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Background: Due to changes in cancer-related risk factors, improvements in diagnostic procedures and treatments,
and the aging of the population, in most developed countries cancer accounts for an increasing proportion of
health care expenditures. The analysis of cancer-related costs is a topic of several economic and epidemiological
studies and represents a research area of great interest to public health planners and policy makers. In Italy studies
are limited either to some specific types of expenditures or to specific groups of cancer patients. Aim of the paper
is to estimate the distribution of cancer survivors and associated health care expenditures according to a disease
pathway which identifies three clinically relevant phases: initial (one year following diagnosis), continuing (between
initial and final) and final (one year before death).
Methods: The methodology proposed is based on the reconstruction of patterns of care at individual level by
combining different data sources, surveillance data and administrative data, in areas covered by cancer registration.
Results: A total colorectal cancer-related expenditure of 77.8 million Euros for 18012 patients (corresponding to
about 4300 Euros per capita) is estimated in 2006 in two Italian areas located in Tuscany and Veneto regions,
respectively. Cost of care varies according to the care pathway: 11% of patients were in the initial phase, and
consumed 34% of total expenditure; patients in the final (6%) and in the continuing (83%) phase consumed 23%
and 43% of the budget, respectively. There is an association between patterns of care/costs and patients
characteristics such as stage and age at diagnosis.
Conclusions: This paper represents the first attempt to attribute health care expenditures in Italy to specific phases
of disease, according to varying treatment approaches, surveillance strategies and management of relapses,
palliative care. The association between stage at diagnosis, profile of therapies and costs supports the idea that
primary prevention and early detection play an important role in a public health perspective. Results from this pilot
study encourage the use of such analyses in a public health perspective, to increase understanding of patient
outcomes and economic consequences of differences in policies related to cancer screening, treatment, and
programs of care.
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In most developed countries, cancer is responsible for an
increasing amount of national health expenditures [1].
The number of newly diagnosed cancer patients is
expected to increase due to population growth and aging
[2]. Furthermore, improvements have been achieved in re-
ducing cancer mortality via prevention, early detection
and effective new therapies, as a consequence the amount
of people living with a cancer is increasing. Health care
delivery trends, including increasing costs of cancer care
and, in particular, increasing use of expensive new chemo-
therapy drugs [3,4] are projected to be associated with in-
creased costs of cancer care. In this context, quantification
of cancer costs is paramount in order to measure the eco-
nomic burden of the disease and to predict the impact of
new medical interventions [5].
The analysis of cancer-related costs is a topic of sev-
eral epidemiological and economic studies. Some are
based on the number of newly diagnosed cases (incident
cases), others are based on survivors at a given calendar
time (prevalent cases) [6]. In the prevalence-based ap-
proach patients are distributed into different disease
phases according to the disease pathway and according
to different care needs [7,8]. The cancer pathway is usu-
ally subdivided into three phases representing clinical
and cost-related dynamic: initial (the time following
diagnosis, usually one year after diagnosis), continuing
(all time occurring between initial and final) and final
(the time before death, usually one year before death).
Most studies on patterns of care and costs of cancer
have been conducted in countries where cancer regis-
tration is nation- or region-wide and prevalence can be
estimated as a function of new cases and life status
follow-up [9]. In these cases, data collected on diagnosis
and life status of all incident cases give the most reliable
basis for estimating prevalence as all new cases occur-
ring in the population covered are registered. Health ex-
penditure data are available both on individual level and
for different cancer sites for specific sub-groups of popu-
lation (as is the case of the Medicare database, which in-
cludes only patients of 65 and over [10]).
In Italy in year 2006 2.2 million of cancer survivors
have been estimated [11]. The total health expenditures
have been quantified as 110 billion euros (7.3% of Gross
Domestic Product) and expenditures attributable to
cancer as 7.5 billion euros, 6.7% of total health expendi-
tures [12]. In Italy there is local experience limited ei-
ther to some specific types of expenditures or to specific
disease phases. Moreover some experience exists on
cost-effectiveness analyses, aimed to evaluate specific
cancer screening programs finalized to early detection
of cases [13-19]. These studies are based on macroeco-
nomic data related to specific procedures or screening
interventions.In this work we aim to: a) estimate the distribution by
phase of care of prevalent cases of colon and rectal can-
cer patients in two Italian areas in 2006, and b) estimate
total direct expenditures sustained by the public health
care system to provide hospital care for those colorectal
cancer survivors for one year, given the age class, the
stage at diagnosis and the phase of care, by using infor-
mation on individual patient pathways of hospital care
(from diagnosis to possible recovery or death). The
paper describes a pilot study innovative with respect to
the previous experiences in the Italian context because it
allows to identify subgroups of cancer survivors homo-
geneous with respect to their health care needs and the
estimation of the corresponding economic resources al-
located to each subgroup during hospitalization. In order
to apply the methodology proposed here, we need to
combine two sources of information: a surveillance
source, containing individual level clinical information
on the patient disease; an administrative source, con-
taining individual level information on the procedures
and interventions undergone by the patient during
hospitalization.
Data and methods
Data needed to estimate the cost profiles and the cancer
survivors are from two different sources: population-
based Cancer Registries (CR) and Hospital Discharge
Cards database (HDC). Data is provided by cancer regis-
tries. The Italian legislation identifies Cancer Registries
as collectors of personal data for surveillance purposes
without explicit individual consent. The approval of a re-
search ethic committee is not required, since this study
is a descriptive analysis of individual data without any
direct or indirect intervention on patients.
Cancer registry database
Population-based cancer registries collect data on all
cancer diagnoses occurring in the population resident in
the area covered by the cancer registration. Patients reg-
istered are then actively followed up with respect to their
vital status, using the information from the National
Death Certificate Database. In Italy cancer registries
cover about 34% of the population and are located
mostly in Northern and Central areas of Italy. In this
study the cancer registries of Veneto and Tuscany [20]
are involved. Veneto Cancer Registry (VCR) covers
about 1.8 millions inhabitants resident in the North-
Eastern region of Veneto, representing 38% of the whole
region [21]. VCR database contains all cases diagnosed
with cancer from 1990 to December 31, 2005 and
followed up to December 31, 2007. Tuscany Cancer
Registry (TCR) covers the population resident in the two
provinces of Firenze and Prato (1.2 million residents),
representing 33% of the whole Tuscany region, located
Table 1 Description of the TCR and LHU-Padua incidence
cohorts 2000-2001
TCR LHU-Padua
(N = 2060) (N = 607)
N % N %
Gender
Male 1135 55.1 356 58.6
Female 925 44.9 251 41.4
Age
15–69 916 44.5 294 48.4
70–79 694 33.7 207 34.1
80–99 450 21.8 106 17.5
TNM stage
I 262 12.7 106 17.5
II 556 27.0 118 19.4
III 537 26.1 162 26.7
IV 397 19.3 135 22.2
unstaged with
surgery
166 8.0 45 7.4
unstaged without
surgery
142 6.9 41 6.8
Vital status at
Dec.31, 2007
Alive 883 42.9 286 47.1
Deaths due to
colorectal cancer
892 43.3 224 36.9
Deaths due to
other cancer




97 4.7 24 4.0
Deaths due to
other causes
83 4.0 34 5.6
Relative survival
(age-adjusted)
Years % s.d. % s.d.
1 82.0 0.91 85.8 1.5
2 73.0 1.10 77.5 1.86
5 60.0 1.33 64.8 2.31
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agnosed with cancer from 1985 to December 31, 2005
and followed up to December 31, 2007. For each patient
the following information is available in the cancer regis-
try: date of birth, date of diagnosis, sex, vital status,
tumor site, morphology, diagnostic confirmation. Data
from VCR and TCR are used to compute the Limited
Duration Prevalence [23], i.e. the number of registered
patients diagnosed with colorectal cancer and still alive
at prevalence date and the Complete Prevalence [24], i.e.
the number of survivors at prevalence date who had a
colorectal cancer as first primary diagnosis in their life.
Hospital discharge card database
In Italy a public welfare system guarantees universal
health care. The national health service is centrally orga-
nized under the Ministry of Health and it is adminis-
tered on a regional basis (19 regions and 2 provinces).
Hospitals are reimbursed by the regional governments
according to the Diagnosis-related group (DRG) system
[25], whereby they receive a lump sum payment for
each patient, determined by the patient’s diagnosis,
health status, and procedures performed during the
hospitalization. For each hospital admission a HDC is
filled by the doctors who take care of the patient. A
HDC refers to a single hospital admission by a single in-
dividual and contains demographic information (date of
birth, sex, place of birth, place of residence), clinical in-
formation (type of diagnosis, interventions and proce-
dures coded by the ICD9-CM classification [26]), and
administrative information (coded by the DRG coding
system). Different HDCs related to the same individual
can be traced thanks to a personal identification code or
to a number of information related to the patient (last
name, first name, gender, date of birth, place of birth).
Study population
Two incident cohorts of colorectal cancer patients diag-
nosed during the period January 1, 2000-January 1, 2002
in the TCR area and in the Local Health Unit (LHU) of
Padua (381.000 inhabitants, about 20% of the entire
VCR area) are considered for linkage to the HDC, in
order to estimate the cost profiles. For these patients in-
formation on stage at diagnosis classified according to
the TNM staging system [27] is also provided, and 15%
of cases with unknown stage (subdivided almost equally
between those who underwent surgery and those who
did not) are excluded from the estimation of cost pro-
files. The main features of the two cohorts are summa-
rized in Table 1 the total number of patients is 2060 for
TCR and 607 for LHU-Padua, with men and women al-
most equally represented, and a similar age structure.
Differences between TCR and LHU-Padua, stage distri-
butions were tested and are statistically significant: withmore Stage I patients in LHU-Padua compared to TCR
and vice versa for Stage II patients. These differences
are possibly due to the cancer registry attitude in the
stage classification and disappear when combining the
two stages.
There is a statistically significant difference between
the relative survival (age-adjusted values according to
Corazziari standard population [28]) of the two cohorts:
LHU-Padua has higher relative survival than TCR during
the entire follow-up span. The main reason for these
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with respect to survival.
Each case from the two incident cohorts is linked to
the HDC database, in order to trace all hospital dis-
charges referred to the patient, starting from his/her
diagnosis up to January 1, 2007. HDC reporting codes of
diagnoses (Additional file 1: Table S1), interventions and
procedures related to colorectal cancer (Additional file 1:
Table S2) and used in the two regions since the beginning
of 2000 are taken into account.
The linkage is deterministic and 95% of all colorectal
cancer cases are linked to one or more HDC: a total
number of 607 patients were linked with 3853 HDC in
LHU-Padua, and a total number of 2060 patients were
linked with 7896 HDC in TCR. Incident cases not
linked with the HDC database are: those diagnosed with
Death Certificate Only (DCO) or discovered at autopsy;
cancer patients who are diagnosed and whose cancer is
treated in outpatient clinic (i.e. outside of the hospital)
or in private hospitals not included in the National
Health System.
Estimation of costs and cost profiles
Reimbursements from the regional government corre-
sponding to individual DRG codes (details in Additional
file 1: Table S3) are used to derive single patient cost
profiles.
Each patient in the cohort spends a varied number of
months in each phase of the disease (initial, continuing,
final) and has a different disease pathway (with one
phase only to three phases) according to the following
criteria:
 diagnosed and dead within 12 months: such patient
may contribute to hospital costs only in the final
phase;
 diagnosed and dead between 13 and 24 months:
such patient may contribute to hospital costs only in
the initial and final phase of the disease; the final
phase has priority over the initial phase;
 diagnosed and alive after 24 months, dead any time
before January 1, 2007: such patient may contribute
to hospital costs in the initial, continuing, and final
phase of the disease;
 diagnosed and still alive at January 1, 2007: such
patient may contribute to hospital costs in the initial
and continuing phase of the disease;
In each disease phase monthly average costs are
obtained by dividing the total costs of the phase by the
total number of person-months in the same phase (com-
putational details in Appendix). Notice that the contri-
bution may be either in terms of person-months and
costs or of person-months only: a patient still alive atprevalence date contributes to the denominator even if
s/he has not being hospitalized and has no hospital
costs. Average costs on yearly basis are obtained by
multiplying the monthly average costs by 12 for each
phase of care.
The set of the values corresponding to the three
phases of care constitutes the yearly cost profile.
In our case HDC collected in the period January 1,
2000 to January 1, 2007 refer to patients diagnosed in
2000-2001, hence initial phase costs are averaged over
the period 2000-2002, continuing phase Table 1 costs
are averaged over the period 2001-2006, and final phase
costs are averaged over the period 2000-2006.
Yearly cost profiles are specific by age class (<70; 70-
79; 80+), chosen according to clinical characteristics and
clinicians attitudes toward treatment options, and in the
initial phase are also specific by stage at diagnosis. Yearly
cost profiles derived for the LHU-Padua are used for the
entire VCR area, assuming a common reimbursement
distribution by phase of care (VCR cost profiles).Statistical methods: prevalence decomposition
Suppose a cancer registry has length of registration of K
years at the beginning of year Y and information on vital
status is available up to year (Y + 1). We are interested
in decomposing the observed prevalent cases into three
components, given by phases of care:
 P1Y are the prevalent cases in the initial phase, that is
cases observed in Y who were diagnosed within the
previous 12 months;
 P2Y are the prevalent cases in the continuing phase,
that is cases observed in Y who were diagnosed
more than 12 months before and are alive at the
beginning of year Y + 1 ;
 P3Y are the prevalent cases in the final phase, that is
cases observed alive in Y who were diagnosed any
time after the initial year (Y-K) and died between Y
and Y + 1.
Prevalent cases in each phase are calculated by age
class (for simplicity we omit the age index) according to
the number of years since diagnosis as follows: let LDPY
denote the Limited Duration Prevalence at January 1,
year Y and let LDPY(j) be the number of prevalent cases
in Y who were diagnosed during the year Y-j , with j = 1,…,
K; these cases have survived j years, therefore have dur-
ation j; both LDPY and LDPY(j) are obtained from the
SEER*Stat software [29] and are adjusted to take into ac-
count lost-to-follow up cases. Similarly let DY(j) be the
number of prevalent cases who die in year Y and were di-
agnosed during the year Y-j, as reported from the National
Death Certificate Database.
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tribution of prevalent cases by phase of care has been
obtained using prevalent cases at January 1, 2006 and
number of deaths occurred from January 1, 2006 to
January 1, 2007, according to the following criteria:
1) The number of prevalent cases in the initial phase
are those cases diagnosed during the year 2005
(incident cohort 2005 diagnosed from January 1 to
December 31) who will survive until January 1,
2007. Prevalent cases in the initial phase have been
further stratified by stage at diagnosis, using the
2000-2002 incidence cohort stage distribution.
2) The number of prevalent cases in the continuing
phase are survivors at January 1, 2006 of duration j
in [2,K] still alive at January 1, 2007. Cases
diagnosed before the registry started its activity and
still alive, can only be in the continuing or final
phase; here we assume that they are in the
continuing phase. The reasoning behind this
assumption is that for Cancer Registries with long
length of activity, it is likely that cases diagnosed
before the cancer registration started and still alive
in Y are cured and will never die for the first
primary tumor they were diagnosed with. More
specifically, when registry length K is higher than
the mean survival time for fatal cases (those who are
bound to die for the cancer considered), survivors
after K years may be considered as cured and can be
entirely attributed to the continuing phase. Previous
studies showed that for colon and rectum cancersFigure 1 Average costs (€) per month of colorectal cancer patients by
pathway of the average reimbursement (in Euros) allocated to hospitals per p
cohort of colorectal cancer cases diagnosed in LHU-Padua and TCR respective
occurred since diagnosis, in the final phase the x-axis measures the time since
month since entrance). The black line represents the LHU-Padua, the gray linethe proportion of cured patients in Italy is about
46% and the mean survival time for fatal cases is
about two years and a half [30]. We therefore expect
that the unobserved prevalent cases in TCR and
VCR in 2006 are all cured and belong to the
continuing phase of the disease.
3) Finally, the number of prevalent cases in the final
phase are those who will die during the year 2006.
Results and discussion
Figure 1 shows the average costs per month by phase of
care in LHU-Padua and TCR, for all patients combined,
regardless of their distribution by age and stage at diag-
nosis. The costs in the figure are expressed in Euros and
represent the average reimbursement allocated to hospi-
tals per patient/per month in each phase of the disease.
In the initial and continuing phases the horizontal axis
measures the time occurred since diagnosis, in the final
phase the horizontal axis measures the time since en-
trance in the final phase (starting from the twelfth up to
the first month since entrance). Notice that by comput-
ing monthly averages, different survival patterns within
the same disease phase are taken into account, because
individuals contribute to costs (numerator) and cases
(denominator) only for the actual number of months
they are in a specific phase. The results show a U-shaped
cost profile, with highest costs in the initial and final
phases of care and lower costs in the continuing phase
of care.
The cost profile shows very high costs during the first
months of the initial phase (about 5000 € per person/phase of care. The figure shows the dynamic along the disease
atient/per month (y-axis) in each phase of the disease of the 2000-2001
ly. In the initial and continuing phases the x-axis measures the time
entrance in the final phase (starting from the twelfth up to the first
represents the TCR.
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the continuing phase (about 200 € per person/month on
average) and then increasing again during the last phase
of the disease. The peak during the last months of life at
the end of the U-shape is caused by the contribution of
short survivors (i.e. those patients who survive less than
three month), these patients have a monthly average cost
of about 4 000 € in the last month of life and about
1 500 € in the second and third months before death.
Consistently with the literature [31] these cases are allo-
cated to the final phase, however their treatments are a
mixture of diagnostic and surgical procedures, which are
more expensive, and terminal care. If we did not con-
sider these cases (which represent 18% in LHU-Padua
and 23% in TCR) the costs of the final phase would be
gradually increasing, without reaching a peak.
Figure 2 show the yearly cost profiles for LHU-Padua
and TCR combined. In Figure 2a each bar represents the
average reimbursement (in Euros) allocated to hospitals
for all cancer-related treatments and procedures pro-
vided to a patient in the initial phase by stage at diagno-
sis (X axis) and age class (different color of the bars). In
Figure 2b each bar represents the average reimburse-
ment (in Euros) allocated to hospitals for all cancer-
related treatments and procedures provided to a patient
by age class (X axis) and phase of care (different color of
the bars).
There is a trend in costs by stage at diagnosis in the
initial phase in all age classes: more advanced stages cor-
respond to higher average costs, patients in stage IV cost
about 70% more than patients in early stages I and II
(Figure 2a). This result is consistent with the clinical
guidelines and recommendations, which suggest differ-
ent treatment strategies according to the tumor stage:
typically, patients with tumor in Stage I are followed up
without adjuvant therapy, while for a portion of high risk




Figure 2 Average yearly costs (€) of colorectal cancer patients for VC
the average yearly costs (in Euros) of the initial phase in the 2000-2001 coh
by stage at diagnosis (x-axis) and age class (dark bar represents 0-69, gray b
illustrates the distribution of the average yearly costs (in Euros) in the 2000
combined, by age at diagnosis (x-axis) and phase of care (dark bar represen
gray bar represents the final phase).surgery could be considered [32,33]; Stage III patients
are treated with a curative surgical resection (possibly
with transient colic anastomosis) and postoperative
chemotherapy is mandatory; standard treatments for
Stage IV patients have primarily palliative intent, and
consist of surgical resection of bowel and/or metastasis,
palliative anastomosis, chemotherapy (possibly in associ-
ation with biological therapy) and radiation therapy to
the primary rectal tumor to palliate bleeding, or to dis-
ease metastasis to palliate pain [34,35]. In this analysis,
the decision to combine Stages I and II, in order to ob-
tain more robust estimates comparable between the two
cancer registries, is justified by the similarity between cost
profiles observed in Stage I and Stage II separately (data
not shown).
Age is also related with costs: younger patients entail
from 40% to 100% more expenditures than oldest pa-
tients (80+) in all phases of the disease. There is a large
debate about the impact of patients age on the decision
making: despite the presence of comorbidities among
elderly patients, age itself might not be a predictor of
outcome, and the efficacy of adjuvant treatments as well
as the toxicity of chemotherapy are similar to the general
population [36]. The U-shape of costs by phase of care
is confirmed for all age classes (Figure 2b), as indicated
in the literature [37]: with 10 to 17 thousands Euros
yearly costs on average for the initial and final phases,
1.7 to 2.9 thousands Euros yearly costs on average for
the continuing phase.
Table 2 illustrates the number of colorectal cancer sur-
vivors (prevalent cases) in 2006 by age class and phase
of care in TCR and VCR respectively, and the corre-
sponding yearly costs in 2006, expressed in Euros. The
picture of the situation is similar in VCR and TCR, with
most prevalent cases and economic resources concen-
trated in the continuing phase, followed by lower pro-




R and TCR combined. a. The histogram illustrates the distribution of
ort of colorectal cancer cases diagnosed in VCR and TCR combined,
ar represents 70-79, light gray bar represents 80+). b. The histogram
-2001 cohort of colorectal cancer cases diagnosed in VCR and TCR
ts the initial phase, gray bar represents the continuing phase, light
Table 2 TCR and VCR prevalent cases at Jan. 1, 2006 and costs (in Euros) by phase care and age class
TCR VCR
Phase of care Age class Prevalent cases Costs (Euros) Prevalent cases Costs (Euros)
Initial 15-69 373 5 778 956 556 9 302 077
70-79 268 3 371 999 342 4 093 306
80-99 190 1 701 665 203 2 445 414
Subtotal (%) All ages (10%) 831 (32%) 10 852 620 (11%) 1101 (36%) 15 840 797
Continuing 15-69 2331 6 45 7 952 2952 9 101 016
70-79 2411 4 187 039 2792 6 053 056
80-99 2306 3 827 130 2214 4 004 222
Subtotal (%) All ages (84%) 7048 (43%) 14 472 121 (83%) 7958 (43%) 19 158 294
Final 15-69 106 1 337 504 156 2 731 404
70-79 134 1 975 533 163 2 339 350
80-99 251 4 650 260 264 4 447 608
Subtotal (%) All ages (6%) 491 (25%) 7 963 297 (6%) 583 (21%) 9 518 362
Total 8370 33 288 038 9642 44 517 453
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total expenditure of 44.5 million euros for 9640 patients
is estimated for VCR, while 33.3 million euros for 8357
patients is for TCR. These figures correspond to about
4300 euros per capita in 2006. The differences between
patterns of prevalent cases and patterns of costs by
phase of care are due to the effect of average costs of
care which varies according to the disease and care path-
way: 83% of cases in the continuing phase correspond to
43% of health expenditure, mainly devoted to monitoring
procedures, which are less costly; 11% of patients in the
initial phase use about 34% of the total budget for diag-
nostic and surgical procedures, that are more costly; final
phase includes only 6% of cases but requires about 23% of
the total budget. The consistency of the distributions of
prevalent cases and costs between the two registries is a
relevant result, being a pre-requirement for extrapolation
of the methodology at regional level.
Conclusions
This paper describes the colorectal cancer burden in 2006
in two Italian areas covered by cancer registration starting
from individual patterns of hospital care. The idea is to
provide the distribution of health care expenditures
according to the disease pathway from first diagnosis to
possible recovery or death, for subgroups of cancer survi-
vors homogeneous with respect to their health care needs.
The phase of care approach here used subdivides care
into three clinically relevant intervals: the first year since
diagnosis, the last year of life and the monitoring or con-
tinuing period. The main advantage of the phase of care
approach is the possibility to describe the distribution by
disease phase of prevalent cases and hospital care expen-
ditures at a given date taking into account the individualpatterns of care during the entire lifespan. The method-
ology requires the registration of new cancer cases and
follow-up information, typically provided by the cancer
registries, and the collection of data on treatments and
corresponding costs, derived from other administrative
sources. To our knowledge this represents the first ex-
perience in Italy in estimating prevalent cases and costs
distribution according to a three- phase of care frame-
work and linking, at individual level, CR information to
the HDC database.
Data linkage is the preliminary step in order to recon-
struct the patterns of care along the entire disease
pathway. Clinical guidelines are insufficient to predict
patterns of care and furthermore compliance with clin-
ical guidelines might vary between geographical areas.
Following the individual record linkage, DRG codes have
been accurately selected in order to identify only colo-
rectal cancer-related treatments, i.e. those treatments
appropriately attributable to the colon and rectum pri-
mary. One of the advantages of this procedure is that it
allows the direct estimation of the net cancer costs,
without using a control cohort of non-cancer subjects
matched to patients by sex, age, location area and phase
of care, as elsewhere proposed in the literature [10]. An-
other advantage is the direct identification of prevalent
cases in the final phase by counting the number of
deaths during the following year – information on life
status follow-up is provided by the CR using the National
Death Certificate Database– rather than estimating a
survival curve, as elsewhere proposed [8].
Stage is a key variable in this study, because it deter-
mines the treatment approach and the corresponding
patterns of care and costs. Stage classification is a com-
plex issue, and different attitudes in the definition of
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data between cancer registries. In our study, however, stage
at diagnosis is used merely as a proxy of treatment ap-
proach and an accurate stage classification is not required.
In the disease phase framework the number of phases
and length of each phase are a-priori defined and do not
vary according to cancer site or patients characteristics;
however, a twelve months initial phase might be too
short compared to the time required to complete some
first course treatments [38]; the continuing phase length
may vary according to patient survival and correspond-
ing care needs depend on additional prognosis factors,
such as the presence of metastases and possible co-
morbidities, which are not taken into account in the
analysis; a flexible estimation of the phase number and
duration based on observed disease pathways of cancer
patients cohorts might therefore be envisaged [39].
Short term survivors are attributed to the final phase
only, regardless of their cause of death and the fact that
they might have received first course procedures and
treatments. This might lead to a possible overestimation
of the number of terminal patients and of the total costs
attributed to final phase. A correction factor based on
the observed proportion of other causes of death in the
incident cohorts could be implemented.
Costs of the initial phase refer to a cohort of patients
diagnosed in 2000-2001 and do not include recent
variations in the cost of drugs and new diagnostic proce-
dures and treatments. Relevant changes in first course
therapies of colorectal cancer patients have been oc-
curred in Italy after 2005. As a further development
other sources of data in addition to in-hospital records
should be included, i.e. data on drugs consumption
and outpatient treatments, in order to obtain a com-
plete estimation of costs directly attributable to a spe-
cific cancer.
In Italy CR’s represent a reliable surveillance source
which however covers a third of the national population
and it is not representative of the whole country; fur-
thermore, most of the areas covered by the CRs corres-
pond only to portions of a region; finally, each region is
an autonomous entity regarding health care administra-
tion. As a consequence of these features, extrapolating
costs at national level is a very complex exercise. On the
other hand extrapolation at regional level is in principle
feasible, but requires some further methodological steps,
such as projecting prevalent cases in areas not covered
by CR’s, which goes beyond the scope of this pilot study,
and will be the goal of a future development.
A validation of our cost estimates using comparable
figures of health care expenditures documented in the
regional budget plans of Veneto [40] and Tuscany [41]
has been carried out: a total health expenditure of 44.5
million Euros and 33.8 million Euros, in VCR and TCRrespectively, is estimated for 9640 and 8357 colorectal
prevalent cases respectively in 2006, and the distribu-
tion of costs by phase of care is similar between the two
cancer registries; the total costs per capita of colorectal
cancer patients, regardless the phase of care, is about 4
300 Euros per year in the two cancer registries com-
bined, and this value is consistent with a total health ex-
penditures of about 5 000 reported in the regional
budget 2008. The comparability of the results between
the two CR areas confirms the consistency with the
clinical guidelines and represents a first step for future
analyses with the aim to extrapolate local results to the
entire regions.
Finally, the methodology proposed and applied in this
paper may be improved with a projection tool in order
to evaluate the impact of specific public health inter-
ventions on patterns of care and costs of cancer pa-
tients. The analysis of the effects of cancer control
strategies, such as screening programs or new treat-
ments introduction, on the expected economic burden
will be an important area for additional research in a
public health perspective.
Appendix
Estimation of average costs by phase of care
Let X be a sample of patients for which we want to esti-
mate the hospital costs and the profile of costs according
to phase of care f (= 1,…,3), age group a (= 1,…,3), and
stage at diagnosis s (= 1,…,3), and let Xa,s be the sub-
group of same age and stage at diagnosis.
The cost profile is a 3-dimensional vector
Ca;s ¼ c1a;s; c2a; c3a
 
where the components represent the yearly average costs
of each phase, and are computed as follows:let cfij be the
costs of patient j (Xa,s) in month i (=1,…,M
f) of phase f,
and let sfij denote an indicator of the contribution of pa-
tient j in month i of phase f: sfij is equal to 1 if patient j
is alive in month i of phase f, and equal to 0 otherwise.
In order to compute the yearly average costs of each
phase we must divide the total costs of the phase by the
total number of person-months in the same phase. Total
costs are obtained aggregating the hospitalization costs
of each patient observed in each month associated to
the phase.
In our case we observe
M1 =12 months in phase 1, the initial phase may start
any time between Jan 1, 2000 and Jan 1, 2002 and lasts a
number of months variable for each patient between 0
and 12;
M2 = 72 months in phase 2, because the continuing
phase may start any time between Jan 1, 2001 and Jan 1,
2006, and lasts a number of months variable for each
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follow-up 01/01/2007);
M3 = 12 months in phase 3, because the final phase
may occur any time between Jan 1, 2000 and Jan 1,
2007, and lasts a number of months variable for each pa-
tient between 1 and 12 months.
Furthermore the variable stage at diagnosis only affects
treatments, and consequently costs, in the initial phase,
and will not appear in the continuing and final phase.


























for f = 2,3.
Prevalence decomposition
Let Y indicate the year and K the number of years a
registry has been in activity; let LDPY denote the Limited
Duration Prevalence at year Y (January 1st) , and let
LDPY(j) be the number of prevalent cases in Y who were
diagnosed during year Y-j (j = 1,…,K); these cases have
survived j years, therefore have duration j. Similarly let
DY(j) be the number of prevalent cases who die during
year Y and were diagnosed during year Y-j. We want to
decompose the prevalent cases according to the three
phases of care: initial, continuing, final.
In our context the number of prevalent cases in the initial
phase are those cases diagnosed during the year 2005 (inci-
dent cohort 2005 diagnosed from January 1 to December 31)
who will survive until January 1, 2007. These cases are
derived by subtracting from the number of cases alive at
January 1, 2006 (prevalent cases 2006 of duration 1:
LDP2006(1)) the number of deaths occurred in the incident
cohort 2005 during the year 2006, computed as the aver-
age between the number of deaths occurred in 2006 of
duration 1 (D2006(1)) and the number of deaths occurred
in 2006 of duration 2 (D2006(2)):
P12006 ¼ LDP2006 1ð Þ−
D2006 1ð Þ þ D2006 2ð Þ
2
;
where duration 1 corresponds to the time interval [0,1),
and duration 2 corresponds to the time interval [1,2).The number of prevalent cases in the continuing
phase are survivors at January 1, 2006 of duration j
in [2,K] still alive at January 1, 2007. These cases are
derived by subtracting from the number of prevalent
cases at January 1, 2006 of duration j, the average
number of deaths occurred in 2006 of durations j




LDP2006 jð Þ‐D2006 jð Þ þ D2006 jþ 1ð Þ2
 
Furthermore, we add to the continuing phase cases di-
agnosed before the registry started its activity and still




LDP2006 jð Þ‐D2006 jð Þ þ D2006 jþ 1ð Þ2
 
þ PU2006;
where PU2006 is obtained via the complete prevalence
method and computed in the COMPREV software [42].
Finally, the number of prevalent cases in the final
phase are those who will die during the year 2006. These
cases are derived by summing up all average numbers of









Additional file 1: Table S1. List of colon-rectum cancer-related
hospital diagnoses. Table S2. List of colon-rectum cancer-related hospital
procedures. Table S3. Table of the more frequent Diagnosis Related
Group codes related to colorectal cancer incidence cohorts 2000-2001.
The table contains the list of the most frequent DRG codes (overall
representing about 80% of all cases) associated to colorectal cancer
incidence cohorts 2000-2001. For each DRG [43] description and
related reimbursement rate (cost in Euros) are also reported.
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